The UK has no agreement with the EU about British participation in the establishment of a 'European Defence Union'.<\/p>
The Withdrawal Agreement and Political Declaration provide the option, but no obligation, for the UK to continue to contribute to CSDP operations and missions on a voluntary basis, and where of benefit to UK interests. This does not undermine the UK's sovereignty, our command or control of our Armed Forces nor does it oblige us to participate in a 'defence union' or any EU defence initiatives.<\/p>
The UK will retain full sovereign control over its defence, intelligence services and decision-making after leaving the EU. The UK will also retain control over the deployment of its Armed Forces and their equipment. Any future security partnership negotiated with the EU would reflect this position.<\/p>
The UK currently has no agreements with the EU on military command and control procedures other than those in the Withdrawal Agreement referring to continued participation in CSDP operations and missions during the Implementation Period. UK personnel remain under UK sovereign command at all times.<\/p>
The UK does not have any agreements with the EU on British participation in the 'Five Eyes' community. Any future relationship agreement with the EU will not undermine our partnership with the US, Canada, Australia and New Zealand. The intelligence cooperation between these 'Five Eyes' partners is the broadest, deepest and most advanced of any grouping of nations and we are committed to maintaining it.<\/p>
The UK has not entered into any agreements with the EU to participate in the procurement of military equipment from EU-wide organisations. There are no agreements with the EU about British participation in transfer of nuclear technology licensed to the UK by the US.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4306", "label" : {"_value" : "Biography information for Baroness Goldie"} } , "answeringMemberPrinted" : {"_value" : "Baroness Goldie"} , "dateOfAnswer" : {"_value" : "2020-01-28", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2020-01-28T12:43:19.107Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "11"} , "answeringDeptShortName" : {"_value" : "Defence"} , "answeringDeptSortName" : {"_value" : "Defence"} , "date" : {"_value" : "2020-01-15", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "EU Defence Policy"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government whether any agreements have been made with the EU about British participation in (1) the establishment of a European Defence Union, (2) any military command and control procedures, (3) the future of Five Eyes, (4) the procurement of military equipment from an EU-wide organisation, and (5) the transfer of nuclear technology licensed to the UK by the United States; if so, what are the details of any such agreements; and whether any such agreements are separate to any agreements relating to the UK\u2019s departure from the EU.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3799", "label" : {"_value" : "Biography information for Lord James of Blackheath"} } , "tablingMemberPrinted" : [{"_value" : "Lord James of Blackheath"} ], "uin" : "HL456"} , {"_about" : "http://data.parliament.uk/resources/1156576", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1156576/answer", "answerText" : {"_value" : "
Whilst NHS England and NHS Improvement will regularly review its guidance, at present, there are no plans to revisit the specific recommendations for liothyronine unless new clinical evidence comes to light. Decisions on appropriate treatment for thyroid patients and doses are taken in accordance with a clinical management plan and implemented by the clinician.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4019", "label" : {"_value" : "Biography information for Baroness Blackwood of North Oxford"} } , "answeringMemberPrinted" : {"_value" : "Baroness Blackwood of North Oxford"} , "dateOfAnswer" : {"_value" : "2019-11-04", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-11-04T14:53:13.107Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-10-28", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Liothyronine"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government what action they propose to take in relation to thyroid patients who, having previously had successful treatment on dosages of 20mcg and above of liothyronine, are now facing a restriction on the dosage.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/2024", "label" : {"_value" : "Biography information for Lord Hunt of Kings Heath"} } , "tablingMemberPrinted" : [{"_value" : "Lord Hunt of Kings Heath"} ], "uin" : "HL456"} ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 2, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]} }